BRAF mutations might be more common than supposed in vulvar melanomas.
Sophie WylomanskiMarc G DenisSandrine ThéoleyreRéjane BouquinAudrey ValléeAnne-Chantal KnolMélanie Saint-JeanLucie PeuvrelBrigitte DrenoGaëlle QuéreuxPublished in: Experimental dermatology (2017)
Data on BRAF, NRAS and KIT mutations are scarce in patients with vulvo-vaginal melanomas and are associated with important therapeutic issues. We investigated their prevalence in a cohort of patients with female lower genital tract melanomas between 2003 and 2017. Of the 22 patients, 5 (22.7%) harboured a BRAF mutation, which was much higher than the rate of 5% reported in the literature. One patient, who was tested negative on the primary melanoma, had a NRAS mutation in a cutaneous metastasis. Our data provide a rationale for prospective and repeated mutations testing in female lower genital tract melanomas.
Keyphrases
- wild type
- end stage renal disease
- electronic health record
- metastatic colorectal cancer
- ejection fraction
- newly diagnosed
- systematic review
- big data
- clinical trial
- prognostic factors
- risk factors
- peritoneal dialysis
- case report
- squamous cell carcinoma
- radiation therapy
- machine learning
- mass spectrometry
- patient reported outcomes
- sentinel lymph node